LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Magnolia Compound Is a Potent Anti-Cancer Agent

By Biotechdaily staff writers
Posted on 22 Jul 2008
Cancer researchers have shown that honokiol, a compound isolated from magnolia suppresses tumor growth by inhibiting the activity of the enzyme phospholipase D (PLD).

Honokiol is a biphenolic molecule present in the cones, bark, and leaves of Magnolia grandiflora that has been used in traditional Japanese medicine as an anxiolytic, anti-thrombotic, anti-depressant, anti-emetic, and anti-bacterial. While early research on the effective compounds in traditional remedies simply used whole magnolia bark extracts, known as houpu magnolia, more recent work has identified honokiol and its structural isomer magnolol as the active compounds in magnolia bark.

Elevated phospholipase D (PLD) activity provides a survival signal in several human cancer cell lines and suppresses apoptosis when cells are subjected to the stress of serum withdrawal. The tumor promoting effects of PLD are lined to the activity of RAS, which drives molecular pumps that remove chemotherapy drugs from cancer cells.

Investigators at the Emory University School of Medicine (Atlanta, GA, USA) used human cell lines growing in culture to evaluate the dependence of PLD survival signals on Ras and the effect of honokiol on Ras activation.

Results published in the July 2008 issue of the journal Clinical Cancer Research revealed that PLD activity was commonly elevated in response to the stress of serum withdrawal, and that the stress-induced increase in PLD activity was selectively suppressed by honokiol. The stress-induced increase in PLD activity was accompanied by increased Ras activation, and the stress-induced increase in PLD activity in MDA-MB-231 breast cancer cells was dependent on a Ras. These results allowed the authors to conclude that honokiol may be a valuable therapeutic reagent for targeting a large number of human cancers that depend on Ras and PLD for their survival.

"Knowing more about how honokiol works will tell us what kinds of cancer to go after,” said senior author Dr. Jack Arbiser, associate professor of dermatology at Emory University School of Medicine. "We found that it is particularly potent against tumors with activated Ras. Honokiol could be effective as a way to make tumors more sensitive to traditional chemotherapy.”


Related Links:
Emory University School of Medicine
Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more